Category: HCC in Focus
Update on Nivolumab Plus Ipilimumab Combination Therapy for Patients With Hepatocellular Carcinoma
G&H What is the reasoning behind combining nivolumab and ipilimumab to treat patients with hepatocellular carcinoma? PG Over the years, we have learned that immune checkpoint […]
Checkpoint Inhibitor Combinations for Hepatocellular Carcinoma Treatment
G&H What are the advantages of using checkpoint inhibitors for treatment of hepatocellular carcinoma? LK Immune checkpoint inhibitors (CPIs) were first studied in patients with advanced […]
Highlights From the Recent APASL Guidelines on Systemic Therapy for Hepatocellular Carcinoma
G&H Why were guidelines recently released by the Asian Pacific Association for the Study of the Liver on systemic therapy for patients with hepatocellular carcinoma? GL […]
Hepatocellular Carcinoma Surveillance Following Hepatitis C Virus Cure
G&H What is the current understanding of the effect of hepatitis C virus cure on the risk of hepatocellular carcinoma? PK There have been tremendous advances […]
Emerging Strategies for Hepatocellular Carcinoma Surveillance
G&H What are the advantages and disadvantages of using ultrasound for hepatocellular carcinoma surveillance? AS Ultrasound has been the mainstay of hepatocellular carcinoma (HCC) surveillance for […]
Update on Hepatocellular Carcinoma Surveillance, Staging, and Therapy
G&H What are the latest recommendations for hepatocellular carcinoma surveillance? SE All patients with cirrhosis from any cause and those with hepatitis B who are noncirrhotic, […]
Current Status of the Liver Imaging Reporting and Data System in Hepatocellular Carcinoma
G&H What are the current uses of the Liver Imaging Reporting and Data System in hepatocellular carcinoma, and what are its main categories? VC There are […]
Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma
G&H What is the rationale for using durvalumab and tremelimumab in combination for the treatment of hepatocellular carcinoma? RK Durvalumab (Imfinzi, AstraZeneca) and tremelimumab (Imjudo, AstraZeneca) […]
Current Status of Hepatocellular Carcinoma Surveillance
G&H What evidence is currently available showing the benefits of hepatocellular carcinoma surveillance? NP The benefits of hepatocellular carcinoma (HCC) surveillance have been evaluated in several […]
Selective Internal Radiation Therapy Using Yttrium-90 in Early and Intermediate Hepatocellular Carcinoma
G&H How does selective internal radiation therapy using yttrium-90 work? RS Selective internal radiation therapy (SIRT), also known as radioembolization, involves the intra-arterial injection of micron-sized […]
Hepatocellular Carcinoma and Hepatitis Delta Virus
G&H Is hepatitis delta virus oncogenic? NR The simple answer is yes, although hepatitis delta virus (HDV) is not yet labeled as a carcinogenic virus. It […]
Detection of Early-Stage Hepatocellular Carcinoma Using Abbreviated Magnetic Resonance Imaging
G&H How does abbreviated magnetic resonance imaging differ from conventional magnetic resonance imaging? NP Several protocols exist for abbreviated magnetic resonance imaging (MRI), but in general […]
The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma
G&H What are the treatment goals in hepatocellular carcinoma? RK In hepatocellular carcinoma (HCC), the treatment goals depend on the stage of the cancer. For early-stage […]
The Use of Albumin-Bilirubin Grade in Patients With Hepatocellular Carcinoma
G&H How and why did albumin-bilirubin grade come to be used in patients with hepatocellular carcinoma? PG Over a decade ago, the SHARP trial demonstrated the […]
Exploring the Potential Chemoprophylactic Role of Carvedilol for Hepatocellular Carcinoma
G&H What are the notable risk factors for hepatocellular carcinoma? RS The main risk factor for hepatocellular carcinoma (HCC) is liver cirrhosis. A damaged liver with […]
The Role of Liver Biopsy in Hepatocellular Carcinoma
Gastroenterology & Hepatology October 2016, Volume 12, Issue 10 Richard S. Finn, MD Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology Geffen School of […]
Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
Gastroenterology & Hepatology Volume 12, Issue 8, August 2016 Jean-Francois H. Geschwind, MD Chairman, Department of Radiology and Biomedical Imaging Professor of Radiology and Oncology Yale […]
Surveillance for Hepatocellular Carcinoma
Gastroenterology & Hepatology Volume 12, Issue 6, June 2016 Catherine Frenette, MD Medical Director of Liver Transplantation Scripps Center for Organ Transplantation La Jolla, California G&H […]
The Relationship Between Hepatocellular Carcinoma and Hepatitis B and C Virus
Gastroenterology & Hepatology February 2016, Volume 12, Issue 2 Anita Kohli, MD, MS Infectious Disease Physician/Scientist Chair of Research, Department of Medicine Director of Research, Department […]
The Use of Genetic Alterations in the Development of Liver Cancer Drugs
Gastroenterology & Hepatology December 2015, Volume 11, Issue 12 Ghassan K. Abou-Alfa, MD Associate Professor Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical […]